AJANTA PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,333 INR | -3.27% |
|
-3.69% | +11.97% |
| 03/05 | INDIA STOCKS-India's Nifty 50 slips from record high as IT stocks weigh | RE |
| 02/05 | Ajanta Pharma's Consolidated Profit Nearly Doubles in Fiscal Q4 | MT |
| Sales 2024 | 4.21TCr 50Cr | Sales 2025 * | 4.73TCr 57Cr | Capitalization | 29TCr 349.33Cr |
|---|---|---|---|---|---|
| Net income 2024 | 816.2Cr 9.79Cr | Net income 2025 * | 945.7Cr 11Cr | EV / Sales 2024 | 6.67 x |
| Net cash position 2024 * | 797.1Cr 9.56Cr | Net cash position 2025 * | 838.6Cr 10Cr | EV / Sales 2025 * | 5.98 x |
| P/E ratio 2024 |
34.4
x | P/E ratio 2025 * |
31.2
x | Employees | 7,713 |
| Yield 2024 * |
0.87% | Yield 2025 * |
0.77% | Free-Float | 33.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ajanta Pharma Limited
| 1 day | -3.27% | ||
| 1 week | -3.69% | ||
| 1 month | +5.31% | ||
| 3 months | +5.67% | ||
| 6 months | +18.07% | ||
| Current year | +11.97% |
1 week
2 151.00
2 449.00
1 month
2 151.002 540.00
Current year
1 998.352 540.00
1 year
1 301.802 540.00
3 years
1 061.772 540.00
5 years
550.002 540.00
10 years
285.602 540.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 01/99/01 | |
| Chief Executive Officer | 52 | 01/96/01 | |
| Director of Finance/CFO | 59 | 23/98/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 01/96/01 | |
| Chairman | 77 | 31/79/31 | |
| Director/Board Member | 78 | 20/08/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 112 M€ | +4.61% | - | |
| 0.00% | 34 M€ | +3.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 2,333 | -3.27% | 112,849 |
| 30/24/30 | 2,412 | +0.71% | 173,906 |
| 29/24/29 | 2,395 | -0.93% | 82,572 |
| 28/24/28 | 2,418 | -0.71% | 41,522 |
| 27/24/27 | 2,435 | +0.50% | 80,372 |
Delayed Quote NSE India S.E., May 31, 2024 at 05:13 pm IST
More quotes
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
Sector
Pharmaceuticals
Calendar
25/07/2024
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2,333
INR
Average target price
2,440
INR
Spread / Average Target
+4.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.97% | 349.14Cr | |
| +15.91% | 4.2TCr | |
| +22.40% | 2.23TCr | |
| +18.48% | 1.52TCr | |
| +16.12% | 1.4TCr | |
| +45.12% | 1.21TCr | |
| -9.58% | 679.6Cr | |
| -0.05% | 678.76Cr | |
| -8.87% | 572.55Cr | |
| +14.18% | 549.33Cr |
- Stock Market
- Equities
- AJANTPHARM Stock
